The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.

Rahim A, O'Neill PA, Shalet SM

Clinical endocrinology1 Jan 1999Cited by 10 (Europe PMC)

PMID10341859DOI10.1046/j.1365-2265.1999.00609.xPepBankPUB-10341859

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialOther
In subjects given hexarelin for 16 weeks, the area under the cortisol curve was significantly lower at week 16 than at baseline.
In plain wordsAfter 16 weeks of hexarelin, the cortisol response to the morning dose was lower than at baseline.
Peptide
Hexarelin
Outcome
DecreaseCortisol AUC at week 16 versus baseline
Study
n: not reported in source
Comparator
baseline
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
AUCCORT
1506 nmol/l/h
baseline
AUCCORT
1222 nmol/l/h
week 16
Source sentences
Summary
Compared with baseline, AUCCOPRT had decreased significantly (P < 0.05) after 16 weeks of hexarelin therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean (+/- SEM) area under the cortisol curve (AUCCORT) at baseline, week 16 and week 20 were 1506 (+/- 77) nmol/l/h, 1222 (+/- 92) nmol/l/h and 1586 (+/- 58) nmol/l/h, respectively.
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185901
02HumanNon-randomized trialOther
Four weeks after hexarelin therapy ended, the area under the cortisol curve rose significantly compared with week 16 and no longer differed from baseline.
In plain wordsFour weeks after hexarelin stopped, the cortisol response rose again and matched baseline.
Peptide
Hexarelin
Outcome
IncreaseCortisol AUC 4 weeks after stopping hexarelin
Study
n: not reported in source
Comparator
week 16
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
AUCCORT
1222 nmol/l/h
week 16
AUCCORT
1586 nmol/l/h
week 20
Source sentences
Summary
Four weeks after completion of hexarelin therapy, the AUCCORT increased significantly compared with AUCCORT at week 16 (P < 0.01) and was no longer significantly different from baseline values.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean (+/- SEM) area under the cortisol curve (AUCCORT) at baseline, week 16 and week 20 were 1506 (+/- 77) nmol/l/h, 1222 (+/- 92) nmol/l/h and 1586 (+/- 58) nmol/l/h, respectively.
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185902
03HumanNon-randomized trialSafety outcome
Chronic hexarelin therapy caused no significant change in 24-h urinary free cortisol.
In plain wordsLong-term hexarelin did not change cortisol in the urine.
Peptide
Hexarelin
Outcome
No significant change24-h urinary free cortisol
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period.
1 context sentence(design, population, supporting numbers)
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185903
04HumanNon-randomized trialSafety outcome
Chronic hexarelin therapy caused no significant change in basal cortisol.
In plain wordsLong-term hexarelin did not change basal cortisol.
Peptide
Hexarelin
Outcome
No significant changeBasal cortisol
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period.
1 context sentence(design, population, supporting numbers)
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185904
05HumanNon-randomized trialSafety outcome
Chronic hexarelin therapy caused no significant change in the area under the ACTH curve.
In plain wordsLong-term hexarelin did not change the ACTH response.
Peptide
Hexarelin
Outcome
No significant changeACTH AUC
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period.
1 context sentence(design, population, supporting numbers)
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185905
06HumanNon-randomized trialSafety outcome
Chronic hexarelin therapy caused no significant change in cortisol binding globulin.
In plain wordsLong-term hexarelin did not change cortisol binding globulin.
Peptide
Hexarelin
Outcome
No significant changeCortisol binding globulin
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period.
1 context sentence(design, population, supporting numbers)
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185906
07HumanNon-randomized trialSafety outcome
Chronic hexarelin therapy caused no significant change in the area under the prolactin curve.
In plain wordsLong-term hexarelin did not change the prolactin response.
Peptide
Hexarelin
Outcome
No significant changeProlactin AUC
Study
n: not reported in source
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
1.5 microg/kg twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
AUCPRL
624 mU/l/h
baseline
AUCPRL
641 mU/l/h
week 16
Source sentences
Summary
There was no significant change in AUCPRL over the study period (P = 0.35).
2 context sentences(design, population, supporting numbers)
Summary · context
The mean (+/- SEM) area under the PRL curve (AUCPRL) at the baseline and week 16 were 624 (+/- 82) mU/l/h and 641 (+/- 83) mU/l/h, respectively.
Summary · context
Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks.
Report a problemFND-1034185907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.